The OrbiMed Israel Fund has completed a $5 million investment in cCam.
cCam’s drug, a monoclonal antibody known as CM-10, is expected to be effective in more than 60 percent of patients eligible for treatment for metastatic melanoma cases
CM-10 derives from research suggesting that tumor cells leverage the CEACAM1 gene in order to evade detection and attack by the body’s immune system. cCam’s technology disrupts communication between the tumor cells and CEACAM1, enabling the immune system’s battery of NK and T cells to destroy the tumor cells. Unlike Yervoy, CM-10 is tumor-site-specific and does not lead to a general activation of the immune system and ensuing adverse side effects.
A major advantage of cCam’s technology, notes CEO Tehila Ben-Moshe, is that the company expects to be able to identify patients that will respond to its therapy through advance screening.
This personalized medicine approach can be expected to lead to an efficient and relatively fast progression through clinical trials.
cCam’s technology may also be effective in the treatment of pancreatic cancer, lung cancer, multiple myeloma and other cancers.